These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23319306)

  • 1. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
    Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
    Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice.
    Switaj T; Jalili A; Jakubowska AB; Drela N; Stoksik M; Nowis D; Basak G; Golab J; Wysocki PJ; Mackiewicz A; Sasor A; Socha K; Jakóbisiak M; Lasek W
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4165-75. PubMed ID: 15217954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
    Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
    Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
    Kajiwara A; Doi H; Eguchi J; Ishii S; Hiraide-Sasagawa A; Sakaki M; Omori R; Hiroishi K; Imawari M
    Oncol Rep; 2012 Jun; 27(6):1765-71. PubMed ID: 22426807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
    Sorrentino R; Morello S; Forte G; Montinaro A; De Vita G; Luciano A; Palma G; Arra C; Maiolino P; Adcock IM; Pinto A
    Am J Respir Crit Care Med; 2011 May; 183(10):1369-79. PubMed ID: 21278302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.
    Le Noci V; Tortoreto M; Gulino A; Storti C; Bianchi F; Zaffaroni N; Tripodo C; Tagliabue E; Balsari A; Sfondrini L
    Oncoimmunology; 2015 Oct; 4(10):e1040214. PubMed ID: 26451303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.
    Zhang M; Yin T; Lu Y; Feng H
    Med Sci Monit; 2016 Apr; 22():1309-17. PubMed ID: 27092689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells.
    Miyagi K; Kawakami K; Kinjo Y; Uezu K; Kinjo T; Nakamura K; Saito A
    Clin Exp Immunol; 2005 May; 140(2):220-9. PubMed ID: 15807845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
    Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.
    Sfondrini L; Besusso D; Bronte V; Macino B; Rossini A; Colombo MP; Ménard S; Balsari A
    Cancer Immunol Immunother; 2004 Aug; 53(8):697-704. PubMed ID: 15034674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
    Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
    J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
    Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
    PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages.
    Sommariva M; Le Noci V; Storti C; Bianchi F; Tagliabue E; Balsari A; Sfondrini L
    Cell Immunol; 2017 Mar; 313():52-58. PubMed ID: 28089340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
    Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
    J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    Najar HM; Dutz JP
    J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
    Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
    Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
    Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
    J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.